Hypoglycemia at the time of Covid-19 pandemic.
Adult
Aged
Aged, 80 and over
Betacoronavirus
/ isolation & purification
Biomarkers
/ analysis
Blood Glucose
/ analysis
COVID-19
Coronavirus Infections
/ complications
Diabetes Mellitus, Type 2
/ physiopathology
Female
Follow-Up Studies
Glycated Hemoglobin
/ analysis
Humans
Hypoglycemia
/ epidemiology
Incidence
India
/ epidemiology
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Prognosis
Retrospective Studies
SARS-CoV-2
Anti-diabetic agents
COVID-19
Comorbidities
Hypoglycemia
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Historique:
received:
10
06
2020
revised:
29
06
2020
accepted:
02
07
2020
pubmed:
16
7
2020
medline:
29
9
2020
entrez:
16
7
2020
Statut:
ppublish
Résumé
Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19) pandemic has further complicated the issue of hypoglycemia due to limitations in access to food, outpatient clinics, pathological services and medicines. To assess the factors associated with the risk of hypoglycemia during April-May 2020 lockdown in people with type 2 diabetes mellitus. We analyzed the data retrospectively from 146 patients of type 2 diabetes mellitus (T2DM) reporting to the emergency department (ED) during lockdown period with symptoms suggestive of hypoglycemia. The majority of patients were male (90/146) with a mean age of 59.88 ± 10.09 years and a mean random blood glucose level of 57.67 ± 9.00 mg/dL. Two-third of patients (70.83%) had level 1 hypoglycemia, while level 2 hypoglycemia was reported in 29.16% of patients. A combination of Metformin and Sulfonylureas (SU) was most commonly associated with the risk of hypoglycemia (65.75%) followed by insulin (33.56%). Subjects who received insulin reported a lower blood glucose value (50.75 ± 8.20 mg/dL) as compared to those receiving a combination of metformin and SU (60.95 ± 7.10 mg/dl). 330.56% of patients who had received prophylaxis hydroxychloroquine (HCQ) 400 mg twice a day along with the routine anti-hyperglycemic agents without their dose adjustment reported hypoglycemia. Patients with hypertension, micro-vascular, macro-vascular complications, and coexistent with each other had a higher propensity to the risk of hypoglycemia (46.58%, 33.56%, 23.29%, and 32.88%) respectively. The COVID-19 lockdown has shown to influence the risk of hypoglycemia in patients with T2DM, especially those receiving SU, insulin, HCQ especially in patients with associated co-morbidities. Patient education, support, and telemedicine plays a pivotal role to prevent hypoglycemia.
Sections du résumé
BACKGROUND
BACKGROUND
Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19) pandemic has further complicated the issue of hypoglycemia due to limitations in access to food, outpatient clinics, pathological services and medicines.
AIM
OBJECTIVE
To assess the factors associated with the risk of hypoglycemia during April-May 2020 lockdown in people with type 2 diabetes mellitus.
METHODOLOGY
METHODS
We analyzed the data retrospectively from 146 patients of type 2 diabetes mellitus (T2DM) reporting to the emergency department (ED) during lockdown period with symptoms suggestive of hypoglycemia.
RESULTS
RESULTS
The majority of patients were male (90/146) with a mean age of 59.88 ± 10.09 years and a mean random blood glucose level of 57.67 ± 9.00 mg/dL. Two-third of patients (70.83%) had level 1 hypoglycemia, while level 2 hypoglycemia was reported in 29.16% of patients. A combination of Metformin and Sulfonylureas (SU) was most commonly associated with the risk of hypoglycemia (65.75%) followed by insulin (33.56%). Subjects who received insulin reported a lower blood glucose value (50.75 ± 8.20 mg/dL) as compared to those receiving a combination of metformin and SU (60.95 ± 7.10 mg/dl). 330.56% of patients who had received prophylaxis hydroxychloroquine (HCQ) 400 mg twice a day along with the routine anti-hyperglycemic agents without their dose adjustment reported hypoglycemia. Patients with hypertension, micro-vascular, macro-vascular complications, and coexistent with each other had a higher propensity to the risk of hypoglycemia (46.58%, 33.56%, 23.29%, and 32.88%) respectively.
CONCLUSION
CONCLUSIONS
The COVID-19 lockdown has shown to influence the risk of hypoglycemia in patients with T2DM, especially those receiving SU, insulin, HCQ especially in patients with associated co-morbidities. Patient education, support, and telemedicine plays a pivotal role to prevent hypoglycemia.
Identifiants
pubmed: 32668399
pii: S1871-4021(20)30249-6
doi: 10.1016/j.dsx.2020.07.003
pmc: PMC7347476
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1146Informations de copyright
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None, Declared.
Références
J Diabetes Complications. 2006 Nov-Dec;20(6):395-401
pubmed: 17070446
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Diabetes Res Clin Pract. 2002 Mar;55(3):209-19
pubmed: 11850097
J Clin Invest. 1987 Mar;79(3):777-81
pubmed: 3546378
Clin J Am Soc Nephrol. 2009 Jun;4(6):1121-7
pubmed: 19423569
Diabetes Metab Syndr. 2020 May - Jun;14(3):211-212
pubmed: 32172175
J Diabetes. 2020 Jan;12(1):91-94
pubmed: 31574564
Diabetes. 2008 Dec;57(12):3169-76
pubmed: 19033403
Diabetes Ther. 2017 Dec;8(6):1405-1413
pubmed: 29086351
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76
pubmed: 31862749
Diabetes Metab Syndr. 2020 May - Jun;14(3):241-246
pubmed: 32247211
Diabetes. 2014 Jul;63(7):2188-95
pubmed: 24962915
Am J Physiol. 1991 Jan;260(1 Pt 1):E67-74
pubmed: 1987794
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):273-276
pubmed: 32283497
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Arthritis Rheum. 2010 Dec;62(12):3569-73
pubmed: 20722019
Diabetes Metab Res Rev. 2020 Mar 31;:e33213321
pubmed: 32233018
N Engl J Med. 2011 Nov 24;365(21):2002-12
pubmed: 22111719
Diabetes Care. 2015 Aug;38(8):1583-91
pubmed: 26207052